IP Verse

Dr H Ulrich Drries competitive analysis

Explore patent oppositions filed by Dr H Ulrich Drries against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jun 25, 2026

Patent Number	Title	Applicant	Opposition Date
EP3791896	Combination Therapy Involving Antibodies Against Claudin 18.2 For Treatment Of Cancer	ASTELLAS PHARMA	Oct 10, 2024
EP3973987	Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Oct 1, 2024
EP3703818	Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Aug 1, 2024
EP4011915	Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Jul 3, 2024
EP3311168	Novel Tnf Structure For Use In Therapy	UCB BIOPHARMA	Feb 12, 2024
EP3827845	Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses	JANSSEN BIOTECH	Dec 22, 2022
EP3157571	Fatty Acids And Their Use In Conjugation To Biomolecules	NOVARTIS	Aug 24, 2022
EP3209783	Permanent Epigenetic Gene Silencing	FONDAZIONE TELETHON	Aug 24, 2022
EP3470432	Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	Jul 5, 2022
EP3107575	Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist	REGENERON PHARMACEUTICALS	May 4, 2022

Discover the latest PTAB cases involving Dr H Ulrich Drries, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Dr H Ulrich Drries with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jun 25, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
DR H ULRICH DRRIES	27	-	-	-
F HOFFMANN LA ROCHE	16	197	-	-
REGENERON PHARMACEUTICALS	38	121	9	32
SANOFI BIOTECHNOLOGY	-	66	-	-